AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28947452 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tests, joint assessment, medical assessment, pain sensitisation tests, ultrasound, CT, MRI, conventional radiographs, fluorescence optical imaging, blood and urine samples, self-reported demographic factors, OA-related questionnaires
Number of subjects: 300
Study 28947452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional analyses
Number of subjects: 300
Study 28947452 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal data
Number of subjects: 300
Study 28947463 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted social marketing intervention targeting GPs
Number of subjects: 0
Study 28947467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatological diagnosis
Number of subjects: 223
Study 28947562 — intervention group
Group type: EXPERIMENTAL
Intervention: Early low-risk survivors (within 6 weeks)
Number of subjects: 12243
Study 28947562 — intervention group
Group type: EXPERIMENTAL
Intervention: Late low-risk survivors (within 1 year)
Number of subjects: 12243
Study 28947562 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with being an early and late postdischarge survivor
Number of subjects: 12243
Study 28948137 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention to promote colorectal cancer (CRC) screening; specific details on dosage and duration not available.
Number of subjects: 0
Study 28948137 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies for the evidence-based intervention; specific details on dosage and duration not available.
Number of subjects: 0
Study 28948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic CVD
Number of subjects: 32095
Study 28948207 — intervention group
Group type: COMPARATOR
Intervention: Non-atherosclerotic CVD
Number of subjects: 32095
Study 28948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic CVD (plural presence)
Number of subjects: 32095
Study 28948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic CVD (singular presence)
Number of subjects: 32095
Study 28948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality (Atherosclerotic CVD)
Number of subjects: 32095
Study 28948207 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality (Non-atherosclerotic CVD)
Number of subjects: 32095
Study 28948656 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 7016
Study 28948656 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 7016
Study 28948656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren and Enalapril
Number of subjects: 7016
Study 28950146 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib 80 mg/d + Lapatinib 1000 mg/d
Number of subjects: 24
Study 28950146 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib 40, 60, or 80 mg + Lapatinib 750, 1000, or 1250 mg
Number of subjects: 24
Study 28950288 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib 50 or 75 mg plus gemcitabine/cisplatin (n=10)
Number of subjects: 55
Study 28950288 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib 50 mg plus gemcitabine/carboplatin (n=9)
Number of subjects: 55
Study 28950288 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib 100 mg plus pemetrexed/carboplatin (n=21)
Number of subjects: 55
Study 28950288 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib 75 mg plus pemetrexed/cisplatin (n=15)
Number of subjects: 55
Study 28950288 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib (various doses) plus chemotherapy
Number of subjects: 55
Study 28950288 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib plus chemotherapy
Number of subjects: 55
Study 28950288 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib 75 mg BID with standard doses of pemetrexed/carboplatin or pemetrexed/cisplatin
Number of subjects: 55
Study 28950288 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib plus gemcitabine-containing regimens
Number of subjects: 55
Study 28950290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 4996
Study 28950290 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 4996
Study 28950298 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg i.v. every 3 weeks until loss of clinical benefit
Number of subjects: 220
Study 28950298 — intervention group
Group type: COMPARATOR
Intervention: Other systemic therapy
Number of subjects: 220
Study 28950298 — intervention group
Group type: COMPARATOR
Intervention: No further systemic therapy
Number of subjects: 220
Study 28950298 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 220
Study 28950309 — intervention group
Group type: COMPARATOR
Intervention: Hospitals without troponin testing
Number of subjects: 15416
Study 28950309 — intervention group
Group type: COMPARATOR
Intervention: Hospitals with ≥ 75% troponin use
Number of subjects: 15416
Study 28950309 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin use in 2011
Number of subjects: 15416
Study 28950309 — intervention group
Group type: EXPERIMENTAL
Intervention: Admissions for NSTEMI
Number of subjects: 15416
Study 28950327 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-fluorescent imaging
Number of subjects: 36
Study 28950338 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (pan HER-family kinase inhibitor)
Number of subjects: 2
Study 28950344 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective cohort (n=5069)
Number of subjects: 10570
Study 28950344 — intervention group
Group type: COMPARATOR
Intervention: Prospective cohort (n=5501)
Number of subjects: 10570
Study 28950372 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily
Number of subjects: 28
Study 28950424 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 0
Study 28950424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28950719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged prothrombin time (PT) with normal thromboelastometry results
Number of subjects: 76
Study 28950783 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoenix Atherectomy System
Number of subjects: 128
Study 28950889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 56
Study 28950889 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel symptoms
Number of subjects: 56
Study 28950889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual symptoms
Number of subjects: 56
Study 28950889 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-existence of urinary and bowel or sexual symptoms
Number of subjects: 56
Study 28950889 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset FRDA
Number of subjects: 56
Study 28950889 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration
Number of subjects: 56
Study 28951336 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with type 1 diabetes
Number of subjects: 7289
Study 28951336 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with type 2 diabetes
Number of subjects: 7289
Study 28951352 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous attention to two objects differing in features (face and house)
Number of subjects: 0
Study 28951352 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous attention to two circular arcs differing in locations
Number of subjects: 0
Study 28951388 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal Microperimetry
Number of subjects: 0
Study 28951417 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective risk perception of stroke and bleeding
Number of subjects: 91
Study 28951417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' judgement of their own knowledge of AF
Number of subjects: 91
Study 28951417 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up events
Number of subjects: 91
Study 28951660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 64
Study 28951660 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 64
Study 28952131 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) program for 4 months
Number of subjects: 37
Study 28952191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipid tolerance test (OLTT)
Number of subjects: 86
Study 28952191 — intervention group
Group type: EXPERIMENTAL
Intervention: NLRP3 (hub gene for inflammation module)
Number of subjects: 86
Study 28952191 — intervention group
Group type: EXPERIMENTAL
Intervention: STARD3 (hub gene for energy metabolism module)
Number of subjects: 86
Study 28952191 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted gene coexpression networks
Number of subjects: 86
Study 28952191 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional ontology analysis of network modules
Number of subjects: 86
Study 28952191 — intervention group
Group type: EXPERIMENTAL
Intervention: G-protein coupled receptor protein signaling pathway
Number of subjects: 86
Study 28952857 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity recommendations
Number of subjects: 297
Study 28952857 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 297
Study 28952881 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised palliative care intervention integrated with standard oncological care
Number of subjects: 44
Study 28952881 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological care
Number of subjects: 44
Study 28952889 — intervention group
Group type: EXPERIMENTAL
Intervention: Incarcerated decedents
Number of subjects: 745
Study 28952889 — intervention group
Group type: COMPARATOR
Intervention: Non-incarcerated decedents
Number of subjects: 745
Study 28953554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor clearance <1.0 mm
Number of subjects: 147
Study 28953554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor clearance <1.5 mm
Number of subjects: 147
Study 28953554 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 <1.0 mm for the SMA-margin
Number of subjects: 147
Study 28953554 — intervention group
Group type: EXPERIMENTAL
Intervention: R1-0 mm posterior-margin for the NAT group
Number of subjects: 147
Study 28953554 — intervention group
Group type: EXPERIMENTAL
Intervention: R0-resection rates
Number of subjects: 147
Study 28953554 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 147
Study 28954004 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hemoglobin oxygen saturation
Number of subjects: 200
Study 28954004 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 200
Study 28954004 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate level
Number of subjects: 200
Study 28954004 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score
Number of subjects: 200
Study 28954004 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused crystalloid volume
Number of subjects: 200
Study 28954004 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of traumatic brain injury
Number of subjects: 200
Study 28954285 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-based stereotactic body radiation therapy (SBRT) with a median dose of 40 GyE (range = 30-50 GyE) in five fractions.
Number of subjects: 89
Study 28954285 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-based SBRT for tumors with KRAS mutation.
Number of subjects: 89
Study 28954716 — intervention group
Group type: COMPARATOR
Intervention: Telephone intervention (n=13)
Number of subjects: 37
Study 28954716 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention (n=24)
Number of subjects: 37
Study 28954781 — intervention group
Group type: EXPERIMENTAL
Intervention: Network analysis approach for understanding ECOPD
Number of subjects: 0
Study 28954781 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28955494 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA + 2.5, 5, 10 or 20 mg/week MTX for 26 weeks (CONCERTO)
Number of subjects: 704
Study 28955494 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA + 7.5 or 20 mg/week MTX for 24 weeks (MUSICA)
Number of subjects: 704
Study 28955496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) enthesis abnormalities
Number of subjects: 402
Study 28955496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) scores
Number of subjects: 402
Study 28955496 — intervention group
Group type: EXPERIMENTAL
Intervention: US structural scores
Number of subjects: 402
Study 28955496 — intervention group
Group type: EXPERIMENTAL
Intervention: PDUS scores
Number of subjects: 402
Study 28955496 — intervention group
Group type: EXPERIMENTAL
Intervention: US enthesophytes
Number of subjects: 402
Study 28955499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0
Study 28955499 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 28955499 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 0
Study 28955501 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA)
Number of subjects: 86
Study 28955501 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model
Number of subjects: 86
Study 28956082 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 24
Study 28956082 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 24
Study 28956281 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector for self-administration of subcutaneous belimumab
Number of subjects: 43
Study 28956335 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE9 inhibition
Number of subjects: 0
Study 28956335 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE inhibitors
Number of subjects: 0
Study 28956335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO)/cGMP pathway and NMDA receptor signaling
Number of subjects: 0
Study 28956734 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion CT
Number of subjects: 92
Study 28956734 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion MR
Number of subjects: 92
Study 28957445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for detection of ≥1 adenoma
Number of subjects: 19968
Study 28957445 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors for detection of ≥1 adenoma
Number of subjects: 19968
Study 28957445 — intervention group
Group type: EXPERIMENTAL
Intervention: Model's discriminative ability
Number of subjects: 19968
Study 28957445 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed vs predicted ADR
Number of subjects: 19968
Study 28958347 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 levels
Number of subjects: 910
Study 28958347 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 therapy
Number of subjects: 910
Study 28958801 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models using genetic data and baseline molecular and clinical variables from patients with Parkinson's disease
Number of subjects: 429
Study 28958801 — intervention group
Group type: EXPERIMENTAL
Intervention: Model ensemble
Number of subjects: 429
Study 28958801 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning approaches
Number of subjects: 429
Study 28959122 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed wheat-based cereals (pHC)
Number of subjects: 9
Study 28959463 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire thrombectomy
Number of subjects: 300
Study 28959463 — intervention group
Group type: COMPARATOR
Intervention: Medical group (control)
Number of subjects: 300
Study 28959486 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery MRI of bilateral carotid arteries and routine brain MRI with standardised protocols
Number of subjects: 1000
Study 28959500 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin combined with R-GDP
Number of subjects: 0
Study 28959913 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analog octreotide + telotristat ethyl (SSA + TE)
Number of subjects: 0
Study 28959913 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin analog octreotide (SSA)
Number of subjects: 0
Study 28960029 — intervention group
Group type: EXPERIMENTAL
Intervention: Submillisievert chest computed tomography (CT) scan (effective dose, 0.19-0.25 millisievert)
Number of subjects: 6
Study 28960029 — intervention group
Group type: EXPERIMENTAL
Intervention: Submillisievert chest computed tomography (CT) scan
Number of subjects: 6
Study 28960096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) at doses of 0.3, 1.0, and 3.0 million cells/kg (up to 250 million cells)
Number of subjects: 30
Study 28960096 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (21 participants)
Number of subjects: 30
Study 28960673 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for heart transplantation (HTx) and left ventricular assist systems (LVAS)
Number of subjects: 99
Study 28960673 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention
Number of subjects: 99
Study 28961153 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed transportation measure
Number of subjects: 244
Study 28961812 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 2000 mg/6 h by intermittent (30 min) or prolonged (3 h) infusion for A. baumannii
Number of subjects: 50
Study 28961812 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 6000 mg/day by continuous infusion for A. baumannii
Number of subjects: 50
Study 28961812 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 2000 mg/8 h or 1000 mg/6 h for P. aeruginosa
Number of subjects: 50
Study 28961812 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1000 mg/8 h for patients with CLCR ≤ 100 mL/min
Number of subjects: 50
Study 28961847 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided multiregion transperineal biopsy
Number of subjects: 49
Study 28962047 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg Dexamethasone Suppression Test (DST)
Number of subjects: 0
Study 28962047 — intervention group
Group type: COMPARATOR
Intervention: 1 mg Dexamethasone Suppression Test (DST)
Number of subjects: 0
Study 28962551 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-like protein 2 (Angptl2) combined index (ACI)
Number of subjects: 460
Study 28962551 — intervention group
Group type: COMPARATOR
Intervention: APRI
Number of subjects: 460
Study 28962551 — intervention group
Group type: COMPARATOR
Intervention: FIB-4
Number of subjects: 460
Study 28962551 — intervention group
Group type: COMPARATOR
Intervention: Hui model
Number of subjects: 460
Study 28962551 — intervention group
Group type: COMPARATOR
Intervention: Forn's index
Number of subjects: 460
Study 28962909 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty and intraoperative radiotherapy (Kypho-IORT)
Number of subjects: 61
Study 28963284 — intervention group
Group type: EXPERIMENTAL
Intervention: The Newborn Behavioral Observation (NBO) - three sessions within the first 4 weeks postdelivery
Number of subjects: 200
Study 28963284 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 28963288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity measures (BMI, WHtR, CUN-BAE, BRI)
Number of subjects: 2354
Study 28963288 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVI
Number of subjects: 2354
Study 28963288 — intervention group
Group type: EXPERIMENTAL
Intervention: baPWV
Number of subjects: 2354
Study 28963288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity measures
Number of subjects: 2354
Study 28963297 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and haemodynamic variables obtained by physical examination and critical care ultrasound (CCUS)
Number of subjects: 704
Study 28963297 — intervention group
Group type: EXPERIMENTAL
Intervention: CCUS images of sufficient quality
Number of subjects: 704
Study 28963297 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused training for obtaining specific CCUS images
Number of subjects: 704
Study 28963316 — intervention group
Group type: EXPERIMENTAL
Intervention: Donation-specific interventions
Number of subjects: 650
Study 28963316 — intervention group
Group type: COMPARATOR
Intervention: Current practices
Number of subjects: 650
Study 28963316 — intervention group
Group type: COMPARATOR
Intervention: Research consent model
Number of subjects: 650
Study 28963316 — intervention group
Group type: COMPARATOR
Intervention: Participation of academic and community hospitals and ODOs
Number of subjects: 650
Study 28963316 — intervention group
Group type: COMPARATOR
Intervention: Accessibility of recipient data
Number of subjects: 650
Study 28963781 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy (356 patients total)
Number of subjects: 1576
Study 28963781 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-a (264 patients)
Number of subjects: 1576
Study 28963781 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-Nucs only (92 patients)
Number of subjects: 1576
Study 28963781 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1576
Study 28964314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg rocuronium
Number of subjects: 75
Study 28964314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rocuronium
Number of subjects: 75
Study 28964314 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (S Group)
Number of subjects: 75
Study 28964326 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 21
Study 28964326 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic men
Number of subjects: 21
Study 28964701 — intervention group
Group type: EXPERIMENTAL
Intervention: REP 2139 and pegylated interferon alfa-2a
Number of subjects: 12
Study 28964736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 1191
Study 28964736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 1191
Study 28964736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab in LDLR-negative heterozygotes
Number of subjects: 1191